The U.S. Food and Drug Administration (FDA) has approved Zepbound® (tirzepatide) as the first-ever prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. Developed by Eli Lilly and Company, this groundbreaking treatment marks a significant advancement for managing OSA when combined with a reduced-calorie diet and increased physical activity.
In Singapore, tirzepatide is marketed under the brand name Mounjaro® and is approved for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:
- as monotherapy when metformin is considered inappropriate due to intolerance or
contraindications - in addition to other medicinal products for the treatment of diabetes
Login to read more
